IONS — Expected Completion of Clinical Trial for Sapablursen in Patients with Polycythemia Vera
Jun 1, 2026, 4:00:00 AM UTC
Summary
Ionis Pharmaceuticals, Inc. is expected to complete a clinical trial for sapablursen in patients with Polycythemia Vera on June 1, 2026. This Phase 2a study evaluates the drug, formerly known as ISIS 702843, in approximately 40 participants and includes four periods: screening, treatment, treatment extension, and post-treatment. The treatment involves subcutaneous injections, with a total of 18 doses administered over roughly 16 months. Currently, the trial is listed as active but not recruiting. The outcome of this study may influence the future market positioning of sapablursen and its potential financial impact on Ionis Pharmaceuticals.
Company
IONIS PHARMACEUTICALS INC (IONS)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ionispharma.comSimilar Events
Completion of SLN124 Clinical Trial in Patients With Polycythemia Vera
Silence Therapeutics plc is set to complete a Phase 1/2 clinical trial of SLN124 in patients with Polycythemia Vera on June 1, 2025. The study aims to assess the drug's safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics through a multicenter, open-label dose escalation followed by a randomized placebo-controlled phase. With an enrollment of 65 participants, the trial is currently recruiting.
Clinical Trial CompletionExpected Completion of Clinical Trial for Rusfertide in Polycythemia Vera
Protagonist Therapeutics, Inc. is expected to complete its clinical trial evaluating the long-term safety of rusfertide in patients with polycythemia vera on April 1, 2027. This open-label Phase 3 study aims to provide long-term treatment and data on the safety and efficacy of rusfertide for subjects showing improved control of hematocrit levels and reduced need for therapeutic phlebotomies. Currently, the trial is enrolling participants by invitation and aims to enroll a total of 50 subjects.
Clinical Trial CompletionExpected Completion of Clinical Trial for Rusfertide in Polycythemia Vera
Protagonist Therapeutics, Inc. is on track to complete its clinical trial assessing the long-term safety and efficacy of rusfertide (PTG-300) in patients with Polycythemia Vera by April 1, 2027. The trial, currently enrolling by invitation, aims to provide ongoing treatment for patients who have previously benefited from rusfertide, with a particular focus on achieving controlled hematocrit levels and reducing the need for therapeutic phlebotomies. This Phase 3 trial is expected to offer significant insights into the long-term impact of rusfertide, potentially influencing its future therapeutic position and market opportunity.
Clinical Trial CompletionExpected completion of Clinical Trial for Splenic Artery Embolization
The clinical trial examining the embolization of the splenic artery after trauma is expected to complete on December 1, 2026. Sponsored by Andrew J. Gunn and conducted at the University of Alabama at Birmingham, the trial involves around 250 participants and is currently in the recruitment phase. The study aims to evaluate the effectiveness of trans-catheter splenic artery embolization (SAE) in preserving the spleen in patients with high-grade splenic injuries, which represent a significant clinical challenge. SAE is recognized as a standard treatment option for hemodynamically stable patients with such injuries. The trial's results may have implications for the standard of care in managing splenic trauma, potentially impacting cost and treatment protocols for future patients.
Clinical Trial Completion